MiMedx Group, an integrated developer, manufacturer and marketer of patent protected biomaterial-based products, has completed the purchase of Surgical Biologics, which expands MiMedx' biomaterial offerings.
With the acquisition, Surgical Biologics will operate as a wholly owned subsidiary of MiMedx Group, a developer of processing amniotic membrane tissues that provide safe, reliable and effective implants.
MiMedx chairman and CEO Parker Pete Petit said that the Surgical Biologics’ proprietary tissue processing technology, Purion, is a complement to their existing HydroFix and CollaFix platform technologies.
"With this transaction, the Surgical Biologics tissue implants are now available to our sales reps and distributors. Combined with our HydroFix Vaso Shield and HydroFix Spine Shield products, the Surgical Biologics tissue implants give MiMedx a broader portfolio that immediately serves the demands and surgical preferences of practicing physicians," Petit said.
The Purion process follows strict guidelines for allograft processing established by the Food and Drug Administration (FDA) and the American Association of Tissue Banks (AATB).